MindMed to Participate in September Investor Conferences

MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has announced its participation in three major investor conferences in September 2024.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/04/2024 - 07:00 AM EDT

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

H.C. Wainwright 26^th Annual Global Investment Conference
- Format: Panel
- Panel Title: Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders
- Date and Time: Tuesday, September 10, 2024 at 3:00 PM ET
- Location: New York, NY
Baird’s 2024 Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Wednesday, September 11, 2024 at 12:15 PM ET
- Location: New York, NY
- Webcast Link: Baird’s 2024 Global Healthcare Conference
2024 Cantor Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Tuesday, September, 17 at 10:20 AM ET
- Location: New York, NY
- Webcast Link: 2024 Cantor Global Healthcare Conference

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.